Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Clinical trial NCT05408845 · RECRUITING

Trial details

NCT number: NCT05408845
Sponsor: NRG Oncology
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Salivary Gland Carcinoma Recurrent Salivary Gland Carcinoma Stage III Major Salivary Gland Cancer AJCC v8 Stage IV Major Salivary Gland Cancer AJCC v8 Unresectable Salivary Gland Carcinoma

Start date: 2023-03-03
Primary completion: 2028-07-31
Enrollment: 146

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.